Savara Inc. announced that one oral and two poster presentations featuring long-term Phase 3 IMPALA-2 trial data for its inhaled GM-CSF therapy molgramostim in autoimmune pulmonary alveolar proteinosis (aPAP) were accepted for the ERS Congress in Barcelona, Spain, held September 5–9, 2026. The focus on sustained efficacy, safety, exercise capacity, and biomarker changes in a rare lung disease with no approved pharmacologic treatments highlights molgramostim’s potential importance for this...

Las acciones de Savara cotizan en el rango medio de los 5 dólares, mientras que los inversores sopesan los recientes cambios de propiedad y el desarrollo.

YARDLEY, PA — Savara Inc. (Nasdaq: SVRA) granted stock options and restricted stock units covering a combined 139,000 shares to eight new employees as the clinical-stage biotechnology company continues development …

Savara Inc. announced that its Phase 3 IMPALA-2 data for molgramostim in autoimmune pulmonary alveolar proteinosis (aPAP) will be featured in one oral and two poster presentations at the ERS Congress in Barcelona in early September 2026, highlighting long-term efficacy, safety, and biomarker findings. The company emphasized that these results point to sustained improvements in lung function, exercise capacity, and quality of life in aPAP patients, a rare group that currently lacks any...

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) reported a wider second-quarter loss as the rare-disease drug developer expanded its commercial operation ahead of a November 22 U.S. regulatory decision on …

YARDLEY, Pa., August 24, 2026--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9, 2026.